{
    "ticker": "AIM",
    "name": "AIM ImmunoTech Inc.",
    "description": "AIM ImmunoTech Inc. is a biotechnology company focused on the development of immuno-pharmaceuticals for the treatment of cancer and viral diseases. Founded in 1984 and based in Ocala, Florida, AIM is dedicated to advancing innovative therapies that enhance the immune system's ability to fight diseases. The company\u2019s lead product candidate, Ampligen, is being investigated for its potential to treat various types of cancer, as well as chronic fatigue syndrome and other viral infections. AIM ImmunoTech has a robust pipeline of clinical studies aimed at exploring the effectiveness of its drug candidates, positioning itself at the forefront of immunotherapy research. The company collaborates with various research institutions and healthcare organizations to further its mission of developing groundbreaking therapies. With a commitment to scientific excellence and patient care, AIM ImmunoTech is striving to make a significant impact in the field of immunotherapy, aiming to improve the quality of life for patients battling serious health challenges.",
    "industry": [
        "Biotechnology",
        "Pharmaceuticals"
    ],
    "headquarters": "Ocala, Florida, USA",
    "founded": "1984",
    "website": "https://www.aimimmunotech.com",
    "ceo": "Thomas K. Equels",
    "social_media": {
        "twitter": "https://twitter.com/AIMImmunoTech",
        "linkedin": "https://www.linkedin.com/company/aim-immunotech-inc/"
    },
    "investor_relations": "https://www.aimimmunotech.com/investors",
    "key_executives": [
        {
            "name": "Thomas K. Equels",
            "position": "CEO"
        },
        {
            "name": "Robert A. W. McGowan",
            "position": "CFO"
        }
    ],
    "product_categories": [
        {
            "category": "Cancer Therapies",
            "products": [
                "Ampligen"
            ]
        },
        {
            "category": "Viral Disease Treatments",
            "products": [
                "Ampligen"
            ]
        }
    ],
    "seo": {
        "meta_title": "AIM ImmunoTech Inc. | Innovating Immunotherapy",
        "meta_description": "Explore AIM ImmunoTech Inc., a leader in biotechnology focused on immuno-pharmaceuticals for cancer and viral diseases. Discover our innovative therapies and research.",
        "keywords": [
            "AIM ImmunoTech",
            "Biotechnology",
            "Immunotherapy",
            "Cancer Treatment",
            "Ampligen"
        ]
    },
    "faq": [
        {
            "question": "What is AIM ImmunoTech known for?",
            "answer": "AIM ImmunoTech is known for developing immuno-pharmaceuticals for cancer and viral diseases, particularly its lead product candidate, Ampligen."
        },
        {
            "question": "Where is AIM ImmunoTech headquartered?",
            "answer": "AIM ImmunoTech is headquartered in Ocala, Florida, USA."
        },
        {
            "question": "Who is the CEO of AIM ImmunoTech?",
            "answer": "The CEO of AIM ImmunoTech is Thomas K. Equels."
        },
        {
            "question": "What are the main products of AIM ImmunoTech?",
            "answer": "The main product of AIM ImmunoTech is Ampligen, which is being studied for various cancer therapies and viral diseases."
        },
        {
            "question": "When was AIM ImmunoTech founded?",
            "answer": "AIM ImmunoTech was founded in 1984."
        }
    ],
    "competitors": [
        "CLLS",
        "VIR",
        "XLRN"
    ],
    "related_stocks": [
        "AMGN",
        "GILD",
        "BMY",
        "JNJ"
    ]
}